New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA) (OCTA)

New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA): Sickle Cell Maculopathy

Sickle cell maculopathy was sparingly mentioned in the literature before despite the fact that sickle cell disease or sickle cell trait is common in people of many areas of the world. This study shows that OCTA is a very valuable, non invasive, office procedure that may well be used in diagnosing this disease.

Study Overview

• Status: Completed
• Conditions: Sickle Cell Retinopathy
• Intervention / Treatment: Device: Optical Coherence Tomography Angiography

Detailed Description

this is a clinical study of two African Canadian patients that were diagnosed with sickle cell trait. I used OCTA to show macular vascular occlusions that usually happen with this disease.

• Study Type: Observational
• Enrollment (Actual): 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

African Canadian adults

Description

Inclusion Criteria: people with sickle cell trait or sickle cell disease -

Exclusion Criteria:

-

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
African Canadians; African Canadians with sickle cell disease maculopathy diagnosed by OCTA.	Device: Optical Coherence Tomography Angiography

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
vascular changes seen in the macular vasculature of people with sickle cell disease/ trait as compared to macular vasculature of normal macula.	in this angiography the delicate vasculature of the macula can be clearly visualized and documented.	through study completion, an average of one year

Collaborators and Investigators

• Sponsor: Dr. S.S. Michel Clinic
• Investigators: Principal Investigator: shawkat s Michel, MD, FRCS Ed, Dr. S.S. Michel Clinic, 214 MHC, 156 street and 87 Ave, Edmonton, AB, Canada

Study record dates

Study Major Dates

• Study Start (Actual): August 21, 2016
• Primary Completion (Actual): January 12, 2017
• Study Completion (Actual): February 21, 2017

Study Registration Dates

• First Submitted: February 22, 2017
• First Submitted That Met QC Criteria: March 1, 2017
• First Posted (Actual): March 3, 2017

Study Record Updates

• Last Update Posted (Actual): March 3, 2017
• Last Update Submitted That Met QC Criteria: March 1, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Diseases
• Other Study ID Numbers: Optical Coherence Tomography

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No